Bosutinib is a Src / Abl dual tyrosine kinase inhibitor approved for the treatment of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), or resistant or intolerant to previous treatments CML. The study compare..
The latest research found that some statins can improve the efficacy of chemotherapy drugs used to treat blood cancer in mouse models. Statins are drugs that treat patients with reduced fat in the blood. They are commonly used to..
On June 8 , the US FDA approved Venetoclax ( VENCLEXTA , AbbVie Inc. and Genentech Inc. ) for patients with chronic lymphocytic leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ), with or without 17p deletion, at least Receive..
Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago, and they have discovered a pair of genetic mutations that may cause fa..
The FDA has granted its breakthrough drug quizartinib a breakthrough treatment. Quizartinib is a FLT3 inhibitor under investigation for the treatment of adult patients with relapsed / refractory FLT3-ITD acute myeloi..
The US Food and Drug Administration approved Venetoclax (Venclexta) combined with rituximab (VenR) for the treatment of patients with chronic lymphocytic leukemia (CLL) based on the minimal residual disease (MRD) data of the phase..
According to the results of the second phase of the study, the combination of standard-care chemotherapy drug azacitidine and the immune checkpoint inhibitor nivolumab ( nivolumab ) showed that the response rate and recurrence..
The US FDA has approved gilteritinib ( Xospata ) for the treatment of adult patients with FLT3 mutation-positive relapse or refractory acute myeloid leukemia ( AML ). When used with gil..
The results of a multi-center phase III clinical trial showed that if elderly patients with chronic lymphocytic leukemia ( CLL ) are treated with a new targeted drug ibrutinib compared with the previously commo..
Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed / refractory chronic lymphocytic leukemia ( CLL ), resulting in a high rate of undetectable minimal residual disease ( uMRD ), which is as..